Rocket Lab Stock Jumps on $8B Iridium Deal and Morgan Stanley Bull Case—July 8

Rocket Lab agreed to buy Iridium Communications for $54 per share in cash and stock, valuing the satellite operator at roughly $8 billion. The deal pairs Rocket Lab’s launch and spacecraft capabilities with Iridium’s established 66-satellite constellation, 2.55 million subscribers, and globally licensed spectrum. Morgan Stanley lifted its bull-case target to $293, implying 260% upside, though execution risks and capital needs remain.

Why Rocket Lab is buying Iridium

Rocket Lab CEO Peter Beck called Iridium “the gold standard in secure, safety-critical global satellite connectivity.” The acquisition creates a vertically integrated business spanning design, manufacturing, launch, and satellite operations. Iridium generated $872 million in revenue in 2025, with 79% from IoT services. The combined company can reduce costs and compete more directly with SpaceX’s Starlink, which raised $85 billion in its June 2026 IPO.

The deal structure and timeline

Iridium shareholders receive $27 in cash and Rocket Lab shares per share, representing a 24% premium over Iridium’s Friday close. Rocket Lab secured a $3.6 billion bridge loan from Deutsche Bank and Wells Fargo to fund the cash portion. Both boards unanimously approved the transaction, which is expected to close in mid-2027, pending shareholder and regulatory approval.

Morgan Stanley’s bull case and valuation risks

Morgan Stanley reiterated its Overweight rating and $105 base case while pushing its bull case to $293. Reaching that price requires Rocket Lab’s Neutron rocket to debut on schedule in Q4 2026, Iridium to close by mid-2027, and major Golden Dome contracts to convert to signed deals. Meyka grades RKLB a B with a 12-month forecast of $132.27, suggesting limited upside from current levels. The stock trades at a 22.2x price-to-book ratio, well above the aerospace sector average.

Market context and competitive pressure

RKLB fell 17% over the past week and 24.2% over the past month as the broader space sector sold off following SpaceX’s IPO. The stock remains up 115% over 12 months and 1,296% over three years. Meyka’s technical indicators show RSI at 38.43 (oversold) and MACD histogram at -1.25 (bearish). Iridium trades at $50.48, down 1.2% on the day, with a Meyka grade of B and 12-month forecast of $17.88, signaling significant downside risk from the $54 deal price.

Final Thoughts

The Iridium acquisition gives Rocket Lab recurring revenue and spectrum assets but requires flawless execution on Neutron, deal closing, and contract wins. With Meyka grading RKLB a B and forecasting $132.27 by year-end, the stock offers limited margin of safety at current levels despite Morgan Stanley’s optimistic bull case.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.